Teprotumumab Update

Dec. 5, 2019

On Friday, Dec. 13th, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet in Silver Spring, MD to discuss teprotumumab, a potential treatment for active thyroid eye disease.

If you are interested in attending in person or submitting a comment to the FDA, please see this link for details.

The FDA's Advisory Committees provide independent advice from outside experts on issues related to human and veterinary drugs, biological products, medical devices, and ...

Read More

Shop 'Til You Drop - And Help the GDATF!

Nov. 8, 2019

Your regular online holiday shopping can help the GDATF fund its patient education and support programs! By purchasing through one of the following channels, online retailers will donate a portion of proceeds to the Graves’ Disease & Thyroid Foundation - at no cost to you!

Amazon Smile Program
iGive
eBay

Read More

Neuropsychiatric Symptoms and Graves'

July 2, 2019

If you enjoyed the GDATF's patient bulletin "What's Wrong With Me? I'm Not Myself Anymore", then you won't want to miss the sequel! "A survey study of neuropsychiatric complaints in patients with Graves’ disease: A reassessment of self-reported symptoms and current practice 20 years later" is now available as an e-manuscript that is free with Kindle Unlimited or $2.99 with Amazon. Many thanks to Dr. James Arruda for conducting this ...

Read More